Loading
CAR-T Cell Therapy Research / Cutaneous Lymphoproliferative Disorders Research / Virus-based Gene Therapy Research · Journal article
Blood Cancer Discovery · August 14, 2026
Encouraging direction, but not yet definitive.
This preclinical study presents a CAR T-cell approach targeting the intracellular WT1 oncoprotein cross-presented by HLA class II molecules, achieving recognition across 18 of 20 tested HLA-II alleles and demonstrating antitumor activity in vitro and in vivo models. The work establishes a framework for CAR therapies against intracellular antigens and suggests potential to overcome HLA-restriction barriers, but clinical efficacy and safety in human subjects remain undemonstrated.
Preclinical experimental study with in vitro and in vivo components. Leukemic cells and in vivo tumor models; HLA-II allele panel (20 alleles tested). Intervention: WT1-CAR T cells targeting intracellular WT1 oncoprotein cross-presented by HLA class II surface molecules.
WT1-CAR T cells recognized WT1330-348 peptide presented by 18 out of 20 tested HLA-II alleles WT1-CAR T cells specifically recognized leukemic cells in a WT1- and HLA-II-dependent manner Antitumor response demonstrated in vitro and in vivo
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work addresses a significant unmet need in CAR T-cell therapy by targeting an intracellular antigen across diverse HLA types, potentially broadening applicability to myeloid malignancies and solid tumors. However, translation to clinical use requires human efficacy and safety studies.
A sound preclinical study demonstrating in vitro and in vivo proof-of-concept for a novel CAR T approach targeting an intracellular antigen across diverse HLA alleles, but without clinical efficacy data or human trial results.
As stated by the source record.
Quoted from the source exactly as published.
This work addresses a significant unmet need in CAR T-cell therapy by targeting an intracellular antigen across diverse HLA types, potentially broadening applicability to myeloid malignancies and solid tumors. However, translation to clinical use requires human efficacy and safety studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Chimeric antigen receptor (CAR) technology has revolutionized B-cell malignancy treatment by enabling T cells to effectively recognize and target lineage-specific surface antigens. However, CAR T cells show limited efficacy against myeloid neoplasms and solid tumors due to challenges in identifying suitable surface targets. In this study, we present a CAR targeting the intracellular WT1 oncoprotein, cross-presented by surface HLA class II (HLA-II) alleles. WT1-CAR T cells, derived from an antibody raised solely against a WT1 peptide, recognized the WT1330-348 peptide promiscuously presented by 18 out of 20 tested HLA-II alleles, overcoming traditional HLA restrictions. WT1-CAR T cells specifically recognized leukemic cells in a WT1- and HLA-II-dependent manner and mediated an antitumor response in vitro and in vivo. This approach broadens CAR-targetable antigens beyond traditional HLA restrictions and offers a promising therapeutic option to a wide and genetically diverse patient population. SIGNIFICANCE: Leveraging the promiscuous binding of HLA-II-peptide complexes, we developed a CAR T-cell approach targeting an intracellular oncoprotein WT1 presented across diverse HLA-II families. Our study establishes a framework for CAR therapies against intracellular antigens, extending potential CAR T-cell applications to new cancer types and patient populations.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.